+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent



Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent



Clinical Infectious Diseases 24(2): 179-184



Invasive fungal infections and their risk factors were prospectively assessed in 130 consecutive liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. Eleven percent (14) of the 130 patients had 17 episodes of invasive fungal infections. These included candidiasis (5%; 6 patients), cryptococcosis (5%; 6), aspergillosis (3%; 4), and chromomycosis (1%; 1). An elevated pretransplantation creatinine level, requirement of dialysis (pretransplantation or posttransplantation), duration of intensive care unit stay after transplantation surgery, and antibiotic use (other than for prophylaxis) within 4 weeks of transplantation were significant risk factors for fungal infections occurring within 100 days of transplantation. For fungal infections occurring after 100 days, persistence of renal dysfunction (serum creatinine level of >2.5 mg/dL at 3 months), dialysis, and histopathologically documented recurrence of hepatitis C virus hepatitis were significant risk factors. Mortality was significantly higher among patients with fungal infections than among all other patients (57% vs. 15%; P = .0009). Our study identified specific risk factors for invasive fungal infections in liver transplant recipients receiving tacrolimus; strategies to prevent fungal infections or to initiate early antifungal therapy might be most effectively targeted at these patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 002878398

Download citation: RISBibTeXText

PMID: 9114144

DOI: 10.1093/clinids/24.2.179


Related references

Risk factors for invasive fungal infections in liver transplant recipients receiving tacrolimus as primary immunosuppression. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36(0): 242, 1996

Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. European Journal of Clinical Microbiology and Infectious Diseases 16(11): 821-826, 1998

Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. European Journal of Clinical Microbiology & Infectious Diseases 16(11): 821-826, 1997

Bloodstream infections in liver transplant recipients receiving tacrolimus. Clinical Transplantation 11(4): 275-281, 1997

Clinical spectrum of invasive cryptococcosis in liver transplant recipients receiving tacrolimus. Clinical Transplantation 11(1): 66-70, 1997

Invasive fungal infection in adult orthotopic liver transplant recipients under tacrolimus. Gastroenterology 110(4 SUPPL ): A1224, 1996

Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. Transplantation 61(3): 396-401, 1996

Bloodstream infections in liver transplant recipients receiving tacrolimus Changing patterns of microbial origin. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 36(0): 242, 1996

Invasive fungal infections in lung transplant recipients receiving prophylactic aerosolized amphotericin B formulations. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 42: 401, 2002

Invasive fungal infections in liver transplant recipients. Experimental and Clinical Transplantation 12 Suppl 1: 110-116, 2014

Invasive fungal infections in lung transplant recipients not receiving routine systemic antifungal prophylaxis: 12-year experience at a university lung transplant center. PharmacoTherapy 31(6): 537-545, 2012

Invasive Fungal Infections in Lung Transplant Recipients Not Receiving Routine Systemic Antifungal Prophylaxis: 12-Year Experience at a University Lung Transplant Center. Yearbook of Pulmonary Disease 2012: 173-174, 2012

Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus). Transplantation Proceedings 30(4): 1401-1402, 1998

Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. Transplantation 77(7): 1066-1070, 2004

Risk factors for invasive fungal infections in liver transplant recipients. Chinese Medical Journal 125(2): 400, 2012